Bantam Pharmaceutical at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Bantam Pharmaceutical brings 2 presentations to ENA 2026 in Barcelona. Its posters cover BTM-3566 and related BTM-class OMA1 activators, from markers of response to first clinical results. The work reports initial safety and pharmacokinetics of intermittent BTM-3566 in advanced solid tumors and a biomarker signature of sensitivity whose prevalence is mapped across 9,850 human tumors.
| Organization | ENA 2026 Attendance |
|---|---|
Bantam Pharmaceutical Durham, NC | |
Clinical-stage company developing oral small molecules, including BTM-3566, that kill cancer cells by targeting mitochondrial dynamics. | Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from Bantam Pharmaceutical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction